Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.

Haematologica · 2024 · PMC11063840 · PMID 37981834

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We observed similar OS and PFS trends in NDMM patients with low MLKL expression or high p62 expression; however, the results did not reach statistical significance ( Online Supplementary Figure S7A, B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.